Literature DB >> 1846017

Nitric oxide synthesis in the CNS endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues.

L E Lambert1, J P Whitten, B M Baron, H C Cheng, N S Doherty, I A McDonald.   

Abstract

Inhibition of nitric oxide production by arginine analogues was examined in three cell systems; macrophages, CNS tissue and endothelial cells. Nitric oxide production was assessed indirectly using in vitro assays measuring nitrite production (macrophages), cGMP elevation (CNS) and acetylcholine-induced relaxation of aortic ring segments (endothelium). NG-monomethyl-L-arginine and NG-amino-L-arginine possessed similar inhibitory activity in all three assays, while NG-nitro-L-arginine displayed a striking selectivity for inhibition of brain and endothelial cell nitric oxide synthesis, with IC50 values of 0.05 microM in the CNS versus 200 microM in macrophages. These results suggest that distinct enzymes are responsible for nitric oxide synthesis in different cell types, and indicate that it may be possible to selectively modulate nitric oxide production in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846017     DOI: 10.1016/0024-3205(91)90426-c

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

Review 1.  Nitric oxide and the pancreas: morphological base and role in the control of the exocrine pancreatic secretion.

Authors:  M D Yago; M Mañas; Z Ember; J Singh
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Distribution and metabolism of NG-nitro-L-arginine and NG-nitro-L-arginine methylester in canine blood in vitro.

Authors:  K Krejcy; S Schwarzacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

3.  Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina.

Authors:  C S Park; C Gianotti; R Park; G Krishna
Journal:  Cell Mol Neurobiol       Date:  1996-08       Impact factor: 5.046

4.  Nitric oxide modulates the release of acetylcholine in the ventral striatum of the freely moving rat.

Authors:  H Prast; H Fischer; E Werner; G Werner-Felmayer; A Philippu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

5.  Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNF alpha and nitrite/nitrate in human septic shock.

Authors:  J A Avontuur; T C Stam; M Jongen-Lavrencic; J G van Amsterdam; A M Eggermont; H A Bruining
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

6.  Cerebrovascular alterations in mice lacking neuronal nitric oxide synthase gene expression.

Authors:  K Irikura; P L Huang; J Ma; W S Lee; T Dalkara; M C Fishman; T M Dawson; S H Snyder; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

7.  Nitric oxide involvement in the peptide VIP-associated inhibitory junction potential in the guinea-pig ileum.

Authors:  X D He; R K Goyal
Journal:  J Physiol       Date:  1993-02       Impact factor: 5.182

8.  Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform.

Authors:  G J Southan; B Zingarelli; M O'Connor; A L Salzman; C Szabó
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform.

Authors:  C Szabó; R Bryk; B Zingarelli; G J Southan; T C Gahman; V Bhat; A L Salzman; D J Wolff
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

10.  Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine.

Authors:  S Pfeiffer; E Leopold; K Schmidt; F Brunner; B Mayer
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.